Principal Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$193M Sell
389,511
-37,012
-9% -$16.4M 0.1% 196
2026
Q1
$190M Buy
426,523
+11,423
+3% +$5.33M 0.1% 187
2025
Q4
$188M Buy
415,100
+8,600
+2% +$3.71M 0.1% 194
2025
Q3
$159M Sell
406,500
-3,305
-0.8% -$1.38M 0.08% 210
2025
Q2
$182M Sell
409,805
-4,566
-1% -$2.1M 0.1% 194
2025
Q1
$201M Buy
414,371
+17,839
+4% +$8.31M 0.11% 170
2024
Q4
$160M Sell
396,532
-13,827
-3% -$6.41M 0.09% 201
2024
Q3
$191M Buy
410,359
+21,649
+6% +$10.4M 0.1% 175
2024
Q2
$182M Buy
388,710
+25,573
+7% +$11.1M 0.11% 166
2024
Q1
$152M Sell
363,137
-5,591
-2% -$2.36M 0.09% 195
2023
Q4
$150M Buy
368,728
+40,005
+12% +$14.8M 0.1% 187
2023
Q3
$114M Sell
328,723
-2,220
-0.7% -$776K 0.08% 208
2023
Q2
$116M Sell
330,943
-2,644
-0.8% -$891K 0.08% 223
2023
Q1
$105M Buy
333,587
+2,463
+0.7% +$739K 0.08% 230
2022
Q4
$95.6M Sell
331,124
-25,034
-7% -$7.63M 0.07% 247
2022
Q3
$103M Buy
356,158
+39,731
+13% +$11.4M 0.08% 216
2022
Q2
$89.2M Buy
316,427
+15,590
+5% +$4.17M 0.07% 249
2022
Q1
$78.5M Sell
300,837
-5,475
-2% -$1.3M 0.05% 311
2021
Q4
$67.3M Sell
306,312
-13,734
-4% -$2.67M 0.04% 358
2021
Q3
$58.1M Buy
320,046
+4,658
+1% +$909K 0.04% 387
2021
Q2
$63.6M Sell
315,388
-11,611
-4% -$2.43M 0.04% 368
2021
Q1
$70.3M Sell
326,999
-21,630
-6% -$4.75M 0.05% 322
2020
Q4
$82.4M Sell
348,629
-18,731
-5% -$4.3M 0.06% 284
2020
Q3
$100M Sell
367,360
-24,321
-6% -$6.71M 0.08% 231
2020
Q2
$114M Buy
391,681
+23,036
+6% +$6.25M 0.1% 212
2020
Q1
$87.7M Buy
368,645
+671
+0.2% +$154K 0.1% 224
2019
Q4
$80.6M Sell
367,974
-9,263
-2% -$1.87M 0.07% 305
2019
Q3
$63.9M Sell
377,237
-1,999
-0.5% -$354K 0.06% 334
2019
Q2
$69.5M Buy
379,236
+1,625
+0.4% +$284K 0.06% 313
2019
Q1
$69.5M Sell
377,611
-1,287
-0.3% -$238K 0.06% 309
2018
Q4
$62.8M Sell
378,898
-5,530
-1% -$958K 0.07% 308
2018
Q3
$74.1M Buy
384,428
+7,957
+2% +$1.42M 0.07% 310
2018
Q2
$64M Sell
376,471
-461
-0.1% -$71.5K 0.06% 341
2018
Q1
$61.4M Sell
376,932
-322
-0.1% -$52.6K 0.06% 356
2017
Q4
$56.5M Buy
377,254
+5,450
+1% +$807K 0.05% 392
2017
Q3
$56.5M Sell
371,804
-8,034
-2% -$1.21M 0.05% 387
2017
Q2
$49M Buy
379,838
+10,471
+3% +$1.26M 0.05% 417
2017
Q1
$40.4M Buy
369,367
+5,907
+2% +$520K 0.05% 401
2016
Q4
$26.8M Sell
363,460
-1,276
-0.3% -$104K 0.03% 547
2016
Q3
$31.8M Buy
364,736
+10,094
+3% +$954K 0.04% 447
2016
Q2
$30.5M Buy
354,642
+9,019
+3% +$779K 0.04% 426
2016
Q1
$27.5M Buy
345,623
+8,413
+2% +$761K 0.04% 442
2015
Q4
$42.4M Buy
337,210
+7,517
+2% +$907K 0.06% 292
2015
Q3
$34.3M Buy
329,693
+6,569
+2% +$844K 0.05% 340
2015
Q2
$39.9M Sell
323,124
-11,541
-3% -$1.45M 0.06% 321
2015
Q1
$39.5M Buy
334,665
+9,803
+3% +$1.17M 0.06% 322
2014
Q4
$38.6M Buy
324,862
+11,445
+4% +$1.29M 0.06% 317
2014
Q3
$35.2M Buy
313,417
+8,469
+3% +$806K 0.06% 326
2014
Q2
$28.9M Buy
304,948
+3,044
+1% +$213K 0.05% 379
2014
Q1
$21.4M Buy
301,904
+3,822
+1% +$303K 0.04% 475
2013
Q4
$22.1M Buy
298,082
+2,820
+1% +$196K 0.04% 452
2013
Q3
$22.4M Sell
295,262
-245,187
-45% -$19.5M 0.05% 411
2013
Q2
$43.2M Buy
+540,449
New +$39.8M 0.1% 258

Other funds holding VRTX

Principal Financial Group's VRTX Position: Q2 2026 in Review

Principal Financial Group reduced its Vertex Pharmaceuticals (VRTX) stake by 8.7% in Q2 2026, selling an estimated $16.4M and leaving 389,511 shares worth $193M. The position accounts for 0.1% of the portfolio, ranked #196.

Principal Financial Group first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $201M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Principal Financial Group held 389,511 shares of Vertex Pharmaceuticals worth $193M as of Q2 2026.
  • Principal Financial Group sold 37,012 Vertex Pharmaceuticals shares in Q2 2026, an estimated $16.4M.
  • Vertex Pharmaceuticals made up 0.1% of Principal Financial Group's portfolio in Q2 2026, its #196 holding.
  • Principal Financial Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Principal Financial Group's Vertex Pharmaceuticals position peaked at $201M in Q1 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.